Coronavirus: The global race to patent a remedy; The Mercury News, February 13, 2020

Lisa M. Krieger, The Mercury News; Coronavirus: The global race to patent a remedy

"As a lethal coronavirus triggers a humanitarian crisis in the world’s most populous nation, who owns the rights to a potential cure?

The Bay Area’s pharmaceutical powerhouse Gilead Sciences is first in line for a Chinese patent for its drug called Remdesivir, which shows promise against the broad family of coronaviruses.

But now a team of Chinese scientists say they’ve improved and targeted its use — and, in a startling move, have also filed for a patent...

“Each side wants to be the entity that came up with the treatment for coronavirus,” said Jacob Sherkow, professor of law at the Innovation Center for Law and Technology at New York Law School. “This is not a knockoff of a Louis Vuitton handbag,”...

Patent protection — and market exclusivity — is the lifeblood of drug companies such as Gilead, creating the incentive to find, test and market a medicine."